Skip to main content

Table 4 Patient details of grade ≥ 2 irAEs and treatment cycles, OR at the time of irAEs onset

From: Correlation between immune-related adverse events and therapeutic effects of nivolumab in patients with malignant pleural mesothelioma

Case irAEs Treatment cycles OR Continuity
1 Grade 3 pneumonitis, grade 2 hypothyroidism 14 SD Discontinue
2 Grade 3 hypophysitis 18 SD Discontinue
3 Grade 2 pneumonitis 31 PR Discontinue
4 Grade 2 hypothyroidism 3 SD Continue
5 Grade 2 rash maculopapular 17 SD Continue
6 Grade 2 bullous dermatitis 3 PR Continue
  1. OR objective response, CR complete response, PR partial response, SD stable disease